Seminars in Nuclear Medicine
Volume 40, Issue 3 , Pages 204-208 , May 2010

Cancer Therapy with Alpha-Emitters Labeled Peptides

  • Ekaterina Dadachova, PhD

      Affiliations

    • Department of Nuclear Medicine, Albert Einstein College of Medicine of Yeshiva University, Bronx, NY
    • Department of Microbiology and Immunology, Albert Einstein College of Medicine of Yeshiva University, Bronx, NY
    • Corresponding Author InformationAddress reprint requests to Ekaterina Dadachova, PhD, Department of Nuclear Medicine, 1695A Eastchester Road, Bronx, NY 10461

References 

  1. Dijkgraaf I, Boerman OC, Oyen WJ, et al. Development and application of peptide-based radiopharmaceuticals. Anti Cancer Agents Med Chem. 2007;7:543–551
  2. Milenic DE, Brady ED, Brechbiel MW. Antibody-targeted radiation cancer therapy. Nat Rev Drug Discov. 2004;3:488–498
  3. Humm JL, Cobb LM. Nonuniformity of tumor dose in radioimmunotherapy. J Nucl Med. 1990;31:75–83
  4. Hassfjell S, Brechbiel MW. The development of the alpha-particle emitting radionuclides 212Bi and 213Bi, and their decay chain related radionuclides, for therapeutic applications. Chem Rev. 2001;101:2019–2036
  5. Søyland C, Hassfjell SP. Survival of human lung epithelial cells following in vitro alpha-particle irradiation with absolute determination of the number of alpha-particle traversals of individual cells. Int J Radiat Biol. 2000;76:1315–1322
  6. Pugliese M, Durante M, Grossi GF, et al. Inactivation of individual mammalian cells by single alpha-particles. Int J Radiat Biol. 1997;72:397–407
  7. Hei TK, Wu L, Liu S, et al. Mutagenic effects of a single and an exact number of alpha particles in mammalian cells. Proc Nal Acad Sci U S A. 1997;94:3765–3770
  8. Hall EJ. Radiobiology for the Radiologist. 4th ed.. Philadelphia, PA: JB Lippincott Company; 1994;
  9. Blakely EA, Kronenberg A. Heavy-ion radiobiology: New approaches to delineate mechanisms underlying enhanced biological effectiveness. Radiat Res. 1998;150:S126–S145
  10. Macklis RM, Lin JY, Beresford B, et al. Cellular kinetics, dosimetry, and radiobiology of alpha-particle radioimmunotherapy: Induction of apoptosis. Radiat Res. 1992;130:220–226
  11. Walicka MA, Vaidyanathan G, Zalutsky MR, et al. Survival and DNA damage in Chinese hamster V79 cells exposed to alpha particles emitted by DNA-incorporated astatine-211. Radiat Res. 1998;150:263–268
  12. Bishayee A, Rao DV, Bouchet LG, et al. Protection by DMSO against cell death caused by intracellularly localized iodine-125, iodine-131 and polonium-210. Radiat Res. 2000;153:416–427
  13. Howell RW, Goddu SM, Narra VR, et al. Radiotoxicity of gadolinium-148 and radium-223 in mouse testes: Relative biological effectiveness of alpha-particle emitters in vivo. Radiat Res. 1997;147:342–348
  14. Azure MT, Archer RD, Sastry KSR, et al. Biological effect of lead-212 localized in the nucleus of mammalian cells: Role of recoil energy in the radiotoxicity of internal alpha-particle emitters. Radiat Res. 1994;140:276–283
  15. Goodhead DT. Initial events in the cellular effects of ionizing radiations: Clustered damage in DNA. Int J Radiat Biol. 1994;65:7–17
  16. Atcher RW, Friedman AM, Hines JJ. An improved generator for the production of 212Pb and 212Bi from 224Ra. Int J Rad Appl Instrum A. 1988;39:283–286
  17. In:  Emran AM editors. Chemists View of Imaging Centers. New York, NY: Plenum Press; 1995;
  18. Boll RA, Malkemus D, Mirzadeh S. Production of actinium-225 for alpha particle mediated radioimmunotherapy. Appl Radiol Isot. 2005;62:667–679
  19. Vaidyanathan G, Boskovitz A, Shankar S, et al. Radioiodine and 211At-labeled guanidinomethyl halobenzoyl octreotate conjugates: Potential peptide radiotherapeutics for somatostatin receptor-positive cancers. Peptides. 2004;25:2087–2097
  20. Vaidyanathan G, Affleck DJ, Schottelius M, et al. Synthesis and evaluation of glycosylated octreotate analogues labeled with radioiodine and 211At via a tin precursor. Bioconjug Chem. 2006;17:195–203
  21. Miao Y, Hylarides M, Fisher DR, et al. Melanoma therapy via peptide-targeted alpha-radiation. Clin Cancer Res. 2005;11:5616–5621
  22. Knör S, Sato S, Huber T, et al. Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancer. Eur J Nucl Med Mol Imaging. 2008;35:53–64
  23. Nayak T, Norenberg J, Anderson T, et al. Comparison of high-versus low-linear energy transfer somatostatin receptor targeted radionuclide therapy in vitro. Cancer Biother Radiopharm. 2005;20:52–57
  24. Nayak TK, Norenberg JP, Anderson TL, et al. Somatostatin-receptor-targeted alpha-emitting 213Bi is therapeutically more effective than beta(–)-emitting 177Lu in human pancreatic adenocarcinoma cells. Nucl Med Biol. 2007;34:185–193
  25. Norenberg JP, Krenning BJ, Konings IRHM, et al. 213Bi-[DOTA0, Tyr3]octreotide peptide receptor radionuclide therapy of pancreatic tumors in a preclinical animal model. Clin Cancer Res. 2006;12:897–903
  26. Lindegren S, Andersson H, Jacobsson L, et al. Synthesis and biodistribution of 211At-labeled, biotinylated, and charge-modified poly-L-lysine: Evaluation for use as an effector molecule in pre-targeted intraperitoneal tumor therapy. Bioconjug Chem. 2002;13:502–509
  27. Kneifel S, Cordier D, Good S, et al. Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-substance P. Clin Cancer Res. 2006;12:3843–3850

 E. Dadachova is a Sylvia and Robert S. Olnick Faculty Scholar in Cancer Research and is supported by the National Institute of Allergy and Infectious Diseases (NIAID) grant AI60507.

PII: S0001-2998(10)00003-6

doi: 10.1053/j.semnuclmed.2010.01.002

Seminars in Nuclear Medicine
Volume 40, Issue 3 , Pages 204-208 , May 2010

Article Tools

* Image Usage & Resolution